DEKA Laser, a subsidiary of El.En. S.p.A. and a global leader in laser and energy-based medical technologies, has introduced its groundbreaking therapy, PelviTouch, for the treatment of erectile dysfunction at the European Society for Sexual Medicine (ESSM) congress.
Initially developed to treat urinary incontinence for both men and women, PelviTouch has now been optimized and tailored by DEKA’s research and development team to address erectile dysfunction, a field in which the company has been a pioneer. The innovative therapy combines advanced magnetic stimulation technology to improve men’s intimate health.
Innovative Treatment for Erectile Dysfunction
PelviTouch utilizes DEKA’s proprietary TOP FMS (TOP Flat Magnetic Stimulation) technology, which generates a magnetic field that acts on the pelvic floor, a critical area for sexual function. This treatment stimulates peripheral nerves, inducing muscle contractions that are more powerful than voluntary muscle action. The result is the strengthening of pelvic muscles and the improvement of erectile function. Furthermore, PelviTouch also helps to relax the muscles, reducing spasms and stiffness—common issues associated with erectile dysfunction and urinary incontinence.
PelviTouch: A Non-Invasive Solution
Paolo Salvadeo, CEO of DEKA and General Manager of El.En. S.p.A., highlighted the company’s commitment to innovation, saying, “PelviTouch exemplifies DEKA’s ability to bring cutting-edge technologies to the market, improving patient care. Our extensive investment in research and clinical studies has led to breakthrough results, and we are proud to offer a treatment that enhances intimate health and sexual wellness.”
Clinical Research and Positive Outcomes
At the ESSM congress, Professor Nicola Mondaini, Associate Professor of Urology, presented the results of studies showing the effectiveness of PelviTouch in treating erectile dysfunction and chronic pelvic pain syndrome (CPPS). PelviTouch has proven to reduce pelvic pain, improve urinary symptoms, and enhance patients’ quality of life, all without the need for invasive procedures.
Dr. Giovanni Corona, President of ESSM and an internationally renowned endocrinologist and andrologist, also presented PelviTouch to the congress. He explained, “By 2025, it is projected that 322 million men worldwide will experience erectile dysfunction. PelviTouch provides a solution to this growing issue by normalizing the pelvic floor and improving erectile function.”
A Breakthrough in Intimate Health
PelviTouch’s treatment involves high-intensity muscle contractions in the pelvic area, which last for a few seconds. These contractions bypass the voluntary muscle action, stimulating the pelvic nerves directly and achieving greater intensity than what is possible through voluntary muscular effort. The therapy also helps relieve muscular stiffness, which is a common problem in conditions like erectile dysfunction.
Additionally, PelviTouch has demonstrated positive effects for patients with urinary incontinence, particularly those experiencing post-prostatectomy stress incontinence. By strengthening the pelvic muscles, the therapy reduces the frequency and urgency of urination.
In conclusion, PelviTouch enters the market as a non-invasive, highly effective, and safe solution for treating male intimate health issues. Combining DEKA’s advanced medical technology with patient wellbeing, PelviTouch offers a new pathway for men seeking non-invasive relief from erectile dysfunction and other pelvic health concerns.
For further details, please visit DEKA Laser’s website.
